Ascendis Pharma A/S

SecurityASND / Ascendis Pharma A/S
InstitutionSei Investments Co
Latest Disclosed Ownership281,473 shares
Latest Disclosed Value $ 60,021,329
Sei Investments Co reports 37.09% increase in ownership of ASND / Ascendis Pharma A/S

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 281,473 shares of Ascendis Pharma A/S (US:ASND) valued at $60,021,303 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 205,319 shares of Ascendis Pharma A/S. This represents a change in shares of 37.09% during the quarter. The current value of the position is $61,020,532 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 281,473 76,154 37.09 60,021 47.04 0.0592
2025-11-13 2025-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 205,319 -31,251 -13.21 40,820 -0.03 0.0439
2025-08-14 2025-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 236,570 -21,443 -8.31 40,832 1.54 0.0473
2025-05-14 2025-03-31 13F/A-1 ASCENDIS PHARMA A SPONSORED ADR 04351P101 258,013 -5,569 -2.11 40,214 10.82 0.0518
2025-05-13 2025-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 263,710 128 36,340 0.0395
2025-02-11 2024-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 263,582 -10,165 -3.71 36,287 -11.22 0.0466
2024-11-12 2024-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 273,747 9,176 3.47 40,873 13.28 0.0531
2024-08-13 2024-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 264,571 -81,615 -23.58 36,082 -31.05 0.0511
2024-05-07 2024-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 346,186 -15,644 -4.32 52,333 14.83 0.0767
2024-02-14 2023-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 361,830 -34,610 -8.73 45,572 22.76 0.0732
2023-11-14 2023-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 396,440 -13,944 -3.40 37,123 1.35 0.0667
2023-08-11 2023-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 410,384 -65,637 -13.79 36,627 -28.24 0.0639
2023-05-12 2023-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 476,021 38,770 8.87 51,039 -4.43 0.0948
2023-02-10 2022-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 437,251 -36,268 -7.66 53,401 9.22 0.1187
2022-11-14 2022-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 473,519 21,718 4.81 48,895 16.41 0.1091
2022-08-15 2022-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 451,801 7,242 1.63 42,001 -19.49 0.0907
2022-05-13 2022-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 444,559 21,868 5.17 52,170 -8.26 0.1049
2022-02-14 2021-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 422,691 33,468 8.60 56,865 -8.34 0.1067
2021-11-12 2021-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 389,223 90,902 30.47 62,039 58.07 0.1302
2021-08-06 2021-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 298,321 35,929 13.69 39,247 16.01 0.0870
2021-05-12 2021-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 262,392 19,290 7.93 33,830 -16.57 0.0852
2021-02-08 2020-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 243,102 8,328 3.55 40,551 11.93 0.1048
2020-12-04 2020-09-30 13F/A-1 ASCENDIS PHARMA A SPONSORED ADR 04351P101 234,774 84,122 55.84 36,229 62.60 0.1049
2020-11-06 2020-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 234,774 84,122 36,229 87,231.3769
2020-08-17 2020-06-30 13F/A-1 ASCENDIS PHARMA A S SPONSORED ADR 04351P101 150,652 64,466 74.80 22,281 129.58 0.0691
2020-08-11 2020-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 65,908 -20,278 9,169 24,871.4006
2020-05-14 2020-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 86,186 20,278 30.77 9,705 5.85 0.0356
2020-02-06 2019-12-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 65,908 899 1.38 9,169 46.42 0.0273
2019-11-12 2019-09-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 65,009 20,938 47.51 6,262 23.39 0.0160
2019-08-14 2019-06-30 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 44,071 18,971 75.58 5,075 71.80 0.0166
2019-05-15 2019-03-31 13F ASCENDIS PHARMA A S SPONSORED ADR 04351P101 25,100 25,100 2,954 0.0099
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.